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1  | INTRODUC TION
Cutaneous T-cell lymphoma (CTCL) is the most common primary 
cutaneous lymphoma, accounting for approximately 75% of all cuta-
neous lymphomas.[1-3] Various prognostic markers are important to 
estimate disease progression and guide therapeutics.[4,5] There are 
various treatment modalities available for mycosis fungoides (MF), 
the most common type of CTCL; skin-derived therapies and UV radi-
ations are preferred for early-stage MF. Systemic therapies are often 
reserved for patients with advanced MF and other types of CTCL. 
These include systemic multi-agent chemotherapies, interferon-α, 
bexarotene, HDAC inhibitors, immunotoxins and allogeneic hemato-
poietic stem cell transplantation.
Hughes et al retrospectively analysed the effectiveness of 
systemic chemotherapy in 144 MF and SS cases; median time 
to next treatment (TTNT) was 3.9 months, which is the shortest 
compared with other systemic therapies.[6] It has been shown that 
systemic chemotherapies did not improve prognosis of patients 
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Abstract
Background: Systemic chemotherapy is often the last resort of advanced cutaneous 
T-cell lymphoma (CTCL). Tumor recurrence and adverse effects of systemic chemo-
therapy are the main limitations.
Objective: We aim to investigate the metabolic alterations in tumor cells after CHOP 
(cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone) chemotherapy.
Methods and Results: In advanced CTCL, CHOP chemotherapy has no survival bene-
fit and the duration of response is significantly inferior to other canonical treatments. 
HIF-1α is significantly elevated in lesions of advanced MF patients as well as tumor 
cell line Hut78 and tumor xenograft mice model. CHOP therapy also increased glyco-
lytic activities in a HIF-1α-dependent manner. In CTCL xenograft tumor mice model, 
lesional cells showed a significant increase in IL-17F after chemotherapy, shifting to-
ward a Th17 phenotype, which process is also regulated by HIF-1α. Echinomycin, 
HIF-1α inhibitor, was co-administered in xenograft tumor mouse models with CHOP 
and showed a significant reduction in tumor growth.
Conclusion: CHOP chemotherapy promotes glycolysis and IL-17 pathways in a HIF-
1α-dependent fashion. Furthermore, HIF-1α blockade is promising as an accompany-
ing agent in systemic chemotherapy for patients with advanced CTCL.
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with early-stage MF.[7,8] Systemic chemotherapy temporarily 
suppresses tumor growth; however, tumor recurs much faster 
compared to other treatment modalities. The molecular basis of 
limited efficacy of aggressive chemotherapy in advanced CTCL is 
still not clear.
It is hypothesized that chemotherapy either alters oncogenic po-
tential of tumor cells or it tunes microenvironment more favourable 
toward tumor growth. Reprogramming of metabolism is critical for 
cancer cells to gain extra energy for proliferation. Although oxida-
tive phosphorylation generates more ATP, cancer cells prefer glycol-
ysis as their main source of energy, aka Warburg effect.[9-11] Indeed, 
inhibition of glycolytic pathways has shown promising results as 
therapeutics for cancers, such as 2-deoxyglucose (2-DG) etc.[12,13]
Hypoxia-induced factor-1α (HIF-1α) is one of the central regu-
lators of cellular metabolism; HIF-1α integrates with hypoxia-re-
sponse element (HRE) of target genes and is implicated in almost 
every aspect of cancer biology: tumor metastasis, angiogenesis, 
energy metabolism, apoptosis, etc HIF-1α specifically upregulates 
pathways involved in glycolysis and decreases substrates for aerobic 
metabolism. HIF-1α is well studied in various types of cancer, includ-
ing hematopoietic malignancies.[14,15] Echinomycin is a quinoxaline 
antibiotic, which binds to HRE sequence and acts as a potent HIF-1α 
inhibitor.[16]
In order to elucidate how systemic chemotherapy affects the 
metabolism and immune regulation of malignant T cells, we utilized 
several model systems and patient samples to show that CHOP 




Patient registry was from the cutaneous lymphoma clinic and gen-
eral dermatology clinic, Department of Dermatology, Ruijin Hospital, 
between 2003 and 2015. The diagnosis of CTCL was based on the 
criteria of the 2005 WHO-EORTC classifications[1] and staging of 
CTCL and MF was based on 2007 ISCL/EORTC recommendations.[17]
2.2 | Generation of tumor xenograft mouse model
We generated ex vivo mouse model of CTCL by inoculating 1*107 
HH cells subdermally to axillary skin of 4-week-old female BABL/c 
nude mice. Full-dose CHOP equivalent to human use resulted in sig-
nificant lethality in mice. Dosage of CHOP regimen was optimized 
to cyclophosphamide 40 mg/kg, doxorubicin 3.3 mg/kg, vincristine 
0.5 mg/kg, prednisone 0.2 mg/kg every week. Once tumor volume 
reaches 150 mm3 (10-15 days after inoculation), CHOP regimen was 
delivered intravenously at weekly basis. In echinomycin-treated 
group, 30 μg/kg echinomycin was given by intraperitoneal injection 
every other day starting at same day of CHOP therapy.
2.2.1 | Flow cytometry
Inoculated tumor cells were isolated from xenograft mouse model 
by passing through a 70-um nylon mesh filter into a 50-mL conical 
tube. Cells were resuspended in PBS and layered over lympho-
lyte M to isolate viable lymphocytes. All cell preparations were 
ACK-lysed and washed before analysis. For surface staining, cells 
were suspended in PBS with 2% FCS containing Fc Block (50 ng/
mL) prior to incubation with fluorochrome-conjugated Abs (anti-
human CD4). The stained cells were analysed with a FACSCanto 
II flow cytometer using FACSDiva software (v6.1.3, Becton 
Dickinson). Data were analysed using FlowJo software (v9.3.2, 
TreeStar).
2.2.2 | Cell culture
HH cells (ATCC, CRL-2105) and Hut78 cells (Shanghai Institute of 
Biochemistry and Cell Biology) were cultured per protocol. CHOP 
regimen were used at following concentration: cyclophosphamide 
27.85 μg/mL, doxorubicin 1.858 μg/mL, vincristine 0.074 μg/mL, 
prednisone 0.0325 μg/mL. Echinomycin was added to culture media 
at final concentration of 1.5 nmol/L.
2.3 | RT-PCR
RNA was extracted either from cells or skin biopsy samples using 
TRIzol® (Life Technologies) and further purified using the RNeasy 
kit with on-column DNase I digestion (Qiagen). For qPCR, 1 μg of 
RNA was reverse-transcribed using iScript™. 0.5 μL was used with 
the SYBR® Green Master Mix, and each reaction was performed 
in triplicate. qRT-PCR was performed on the Bio-Rad iCycler with 
MyIQ single colour real-time PCR detection system module with the 
following parameters: 95°C at 3 minutes, (95°C 10 seconds, 55°C 
30 seconds) Å ~ 40, 95°C 1 minute, 55°C 1 minute. The fold change 
in transcript levels was calculated using the ΔΔCt method. β-actin 
was used as controls.
2.4 | Primers (5′ to 3′)
HIF1A: CATCTCCATCTCCTACCCACA and CTTTTCCTGCTCTGTTTGGTG.
IL17F: GAAGGTGCTGGTGACTGTTG and CCTGTGAAGTGGA 
GGGAATT.
STAT3: GGCACCTTCCTGCTAAGATTC and GGTCTTACCGCTGAT 
GTCCTT.
GLUT1: AGGAGATGAAGGAAGAGAGTCG and TGCTCGTGGAGT 
AATAGAAGACA.
HK2: CATCTGCTTGCCTACTTCTTCA and ATCTGGAGTGGA 
CCTCACAAAG.
GPI: ATACCCTGTGACTTCCTCATCC and AATAGAGTTGGTT 
GGGCGATTT.
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PKM: AGTGTGACGAGAACATCCTGTG and AGAGAAATAAGC 
CCATCATCCA.
ENO1: AAGGGTGTCTCAAAGGCTGTT and TTTTCTGTTCCATC 
CATCTCG.
LDH: TATGGAGTGGAATGAATGTTGC and CCAGGATGTGTAGC 
CTTTGAGT.
3  | RESULTS
3.1 | Limited therapeutic effect of CHOP 
chemotherapy
We retrospectively analysed 18 patients with advanced CTCL (in-
cluding advanced MF, PTCL and c-ALCL) from registry in Cutaneous 
Lymphoma Clinic, Department of Dermatology, Ruijin Hospital. We 
compared the overall survival and duration of response in 9 patients 
received CHOP chemotherapy and 9 patients received non-chem-
otherapy (which includes combination of topical corticosteroids, 
narrow-band UVB and bexarotene). No statistical difference was ob-
served in the distribution of patients between two groups in age and 
gender. There is no significant difference in overall survival between 
CHOP and non-chemotherapy groups (log-rank P = .75, Figure 1A). 
However, compared with patient received non-chemotherapy, pa-
tient in CHOP group has a significantly decreased duration of re-
sponse (time in remission, P = .0034, log-rank hazard ratio = 3.54, 
Figure 1B).
3.2 | HIF-1α is upregulated in advanced MF and 
CHOP chemotherapy
As the initial step to address whether tumor microenvironment is 
altered by CHOP chemotherapy, we focused on HIF-1α, a master 
regulator of cellular metabolism. We first measured lesional HIF1A 
expression in early and advanced MF patients. HIF-1α expression 
was elevated by 2.3-fold in advanced MF (Figure 2A). Mirroring that, 
HIF-1α upregulation was also observed in HuT78 cells after CHOP 
treatment, indicating CHOP therapy tunes tumor cells more hypoxic 
as found in advanced MF (Figure 2B). To examine whether this ef-
fect holds true in a more physiological model, we generated tumor 
xenograft mouse mode: HH cells inoculated in BABL/c nude mice 
(see Method Section). Indeed, HIF-1α expression is significantly in-
creased when xenograft was treated with CHOP. HIF-1α upregula-
tion is reversible with intraperitoneal injection of echinomycin, a 
blocking agent of HIF-1α (Figure 2C).
3.3 | CHOP chemotherapy upregulates glycolysis 
via HIF-1α
Since HIF-1α is a key regulator in cellular metabolism, we sought 
to investigate the glycolysis pathway by measuring the expres-
sion of key enzymes in glycolysis pathway in Hut-78 cell line. 
Expression of GLUT1, HK2, GPI, ENO1 and PKM (transcripts en-
code for glucose transporter 1, hexokinase 2, glucose-6-phos-
phate isomerase, enolase 1 and pyruvate kinase) was significantly 
upregulated by CHOP in Hut78 cells (Figure 2D). Expression of 
LDH-α remained unchanged by CHOP. The same upregulation 
in glycolytic pathways was observed in the xenograft tumor 
(Figure 2E). Addition of echinomycin completely reversed the in-
crease of glycolytic enzymes in both models, indicating a mediat-
ing role of HIF-1α (Figure 2D,E).
3.4 | Increased lesional IL-17F after 
CHOP treatment
Differentiation of either Treg cells or Th17 cells is dependent of gly-
colysis and local oxygen concentrations. IL-17F expressing cells were 
quantified by flow cytometry in inoculated tumors. Single dose of 
CHOP infusion significantly increased lesional IL-17F positive cells 
(Figure 3A-C). Serum IL-17F was measured in 50 MF patients includ-
ing 20 early MF (stages I and IIa) and 30 advanced MF (stages IIb, III 
and IV). A large number of patients with advanced MF had elevated 
circulating IL-17F (Figure 3D).
In Hut78 cell line and xenograft tumor model, IL-17F transcript 
level was upregulated by CHOP, recapitulating the in vivo findings. 
Expressions of HIF-1α, Stat3 and RORγT were also increased by 
CHOP, further elucidating the mechanism of IL-17F upregulation. 
The upregulation was blocked by echinomycin, thus suggesting a key 
regulatory role of HIF-1α (Figure 4A,B).
F I G U R E  1   Limited therapeutic 
effect of CHOP chemotherapy in 
advanced CTCL. Kaplan-Meier plot 
of patients overall survival (A) and 
duration of response (B) between CHOP 
chemotherapy and non-chemotherapy 
groups. Nine advanced CTCL patients 
were included in each group
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3.5 | Therapeutic effect of HIF-1α inhibition in CTCL 
xenograft model
In order to investigate whether HIF-1α inhibition has therapeutic ef-
fect toward advanced CTCL, we tested in tumor xenograft mouse 
model. In this model, weekly CHOP infusion was administered when 
tumor volume reached 150 mm3, after 20 days of weekly infusion, 
tumor size was significantly reduced (Figure 4C). It is worth men-
tioning that such significant difference was no longer observed 
after 40 days, mirroring the limited long-term therapeutic effect of 
F I G U R E  2   CHOP chemotherapy 
promotes tumor cell glycolysis via HIF-
1α. HIF1AmRNA levels were measured 
by real-time PCR in skin biopsy samples 
from lesional skin of early MF (n = 7) 
and advanced MF (n = 10) (A), cell 
lysates of HuT78 cells with treatment 
of CHOP and echinomycin (n = 5) (B) 
and xenograft tumor with treatment 
of CHOP and echinomycin (n = 4)(C). 
(D, E) After treatment with CHOP or 
CHOP + echinomycin, RNA was isolated 
from Hut78 cells or xenograft tumors 
and used for real-time PCR analyses 
of glycolytic enzymes. Expression 
levels in sham group were set to 1. 
Results are normalized to β-actin 
transcript levels. n = 4. All graphs show 
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F I G U R E  3   Increased lesional IL-17F 
after CHOP treatment. (A,B)Sorted Th17 
cells (CD4+, CD17F+) from xenograft 
mouse models after treatment with Sham 
or CHOP regimen. C, Quantification of 
IL-17F positive cell numbers in panel A and 
B, n = 3. (D) Serum IL-17F protein level 
was quantified by ELISA in patients with 
early-stage MF and advanced stage MF. 
All graphs show means ± SEM;*P < .05. 
n = 5
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chemotherapy in advanced CTCL. During CHOP therapy, 30ug/kg 
echinomycin was delivered intraperitoneally once every two days to 
block HIF-1α. Compared with CHOP regimen, combination of echin-
omycin and CHOP showed a more significant reduction of tumor 
sizes starting at the third week. Such reduction is persistent toward 
the 53rd day (Figure 4C).
4  | DISCUSSION
In summary, our study suggests that CHOP chemotherapy alters 
tumor cell glycolysis and IL-17 pathways via HIF-1α. We provided 
potential mechanisms of how systemic chemotherapy failed to 
achieve satisfactory efficacy in advanced CTCL and often leads to 
tumor recurrence.
In patients with advanced CTCL, CHOP chemotherapy leads to 
rapid tumor regression, and however, the duration of response is 
significantly inferior to other canonical treatments. Consistent with 
published studies, CHOP chemotherapy resulted in similar overall 
survival with non-chemotherapy treatments. By using two differ-
ent model systems, HuT78 and tumor xenograft mouse models, we 
confirmed upregulation of HIF-1α after CHOP treatment, which is 
the same change in advanced CTCL. It suggested that CHOP che-
motherapy tunes the tumor in the same manner as in aggressive 
CTCL, altering gene expressions by upregulating HIF-1α, hence pro-
vided rationale of limited efficacy and increased tumor recurrence of 
CHOP chemotherapy in CTCL.
After CHOP chemotherapy and in advanced CTCL, a vicious 
cycle is created where CTCL microenvironment becomes more 
hypoxic, continuous HIF-1α activation drives malignant T cells to-
ward Th17 phenotype. Previous studies revealed that malignant 
T cells can have a Th17 phenotype and induce expression of an-
giogenic factor and MMPs to promote tumor growth.[18,19] IL-17F 
expression correlates with progressive diseases and worse clinical 
outcomes. The increase of IL-17F during CHOP chemotherapy is 
HIF-1α-dependent; supporting that Th17 phenotype is a down-
stream effect of hypoxia. In our study, IL-17 expression is induced 
by Stat3 and RORγT, the same mechanism with other published 
studies[18,20-22]: Stat3 inhibition decreases proliferation and in-
creased survival of CTCL tumor cells in vitro. Mouse model car-
rying activated form of Stat3 showed significant increase of IL-17 
and IL-22 producing T cells. Since all the above downstream effect 
of HIF-1α activation promotes tumor growth and invasion, we uti-
lized xenograft model to reveal the therapeutic effect of HIF-1α 
inhibitor in CTCL mouse model.
Echinomycin is a quinoxaline antibiotic, which has showed its 
therapeutic potentials in a plethora of cancers such as haematologi-
cal malignancies, lung cancer and soft tissue sarcomas.[23,24] Besides 
echinomycin, many anti-cancer medications including digoxin and 
bortezomib showed anti- HIF-1α activities.[25]
In conclusion, CHOP chemotherapy alters tumor cell metabo-
lism through HIF-1α, same mechanism in aggressive CTCL; altering 
glycolysis and IL-17 pathways. Our data provided evidence for the 
limited efficacy of CHOP chemotherapy in CTCL and showed HIF-1α 
F I G U R E  4   Therapeutic effect of 
HIF-1α inhibition in CTCL xenograft 
model. (A,B) mRNA levels of IL17F and 
its regulatory genes: HIF1A, STAT3 
and RORγT were measured by qRT-
PCR in HuT78 cells and xenograft 
tumor with treatment of sham, CHOP 
or CHOP + echinomycin. Results are 
normalized to β-actin transcript levels. 
n = 5. C, Xenograft tumor volume 
(mm3) of mice receiving intraperitoneal 
injections of Sham treatment (black), 
CHOP regimen (blue) and CHOP plus 
echinomycin treatment (red). All graphs 
show means ± SEM; ns, not significant; 
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blockade is promising as a synergic agent with systemic chemother-
apy for patients with advanced CTCL.
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